0001213900-24-003661.txt : 20240116 0001213900-24-003661.hdr.sgml : 20240116 20240116141230 ACCESSION NUMBER: 0001213900-24-003661 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240116 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240116 DATE AS OF CHANGE: 20240116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 24534723 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea191665-8k_inmedpharma.htm CURRENT REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 16, 2024

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

InMed Pharmaceuticals Inc.
Suite 310 - 815 W. Hastings Street,
Vancouver, B.C.
Canada		V6C 1B4
(Address of Principal Executive Offices)		(Zip Code)

Company’s telephone number, including area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 16, 2024, the Company outlined key accomplishments from 2023 and provides key strategic priorities for 2024.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		News release, dated January 16, 2024
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED PHARMACEUTICALS INC.

Date: January 16, 2024	By:	/s/ Eric A Adams
		Eric A Adams
		President & CEO

2

EX-99.1 2 ea191665ex99-1_inmedpharma.htm NEWS RELEASE, DATED JANUARY 16, 2024

Exhibit 99.1


	NASDAQ: INM

	Suite 310-815 W. Hastings St.
	Vancouver, BC, Canada V6C 1B4
	Tel: +1.604.669.7207
	Email: info@inmedpharma.com
	www.inmedpharma.com

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

●

Advancing INM-901 as a multimodal treatment option for Alzheimer’s Disease

●

Advancing INM-089 in the treatment of Age-related Macular Degeneration

●

Actively seeking partnerships to advance INM-755 in Dermatology

●

BayMedica subsidiary continues to focus on revenue growth and market expansion

Vancouver, BC – January 16, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlines key accomplishments from 2023 and provides key strategic priorities for 2024.

Eric A. Adams, InMed President and CEO, commented, “In 2023, we experienced significant progress in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives. Our primary accomplishments throughout the year included a number of key milestones, such as the completion of a Phase 2 clinical trial and the launch of two new preclinical programs targeting the treatment of Alzheimer’s disease and Age-related Macular Degeneration (“AMD”).”

Adams continued, “As we embark on 2024, we are placing increased emphasis on proprietary small molecule drug development candidates in our pharmaceutical pipeline with two exciting new programs addressing critical unmet medical needs. Firstly, INM-901 for the treatment of Alzheimer’s disease is showing promise via multiple mechanisms of action, including an increase in neuroprotection and an improvement in neuronal function via neuritogenesis. Secondly, INM-089 for the treatment of AMD appears to play a role in the preservation of retinal function, proactively protecting the retinal cells that are responsible for vision. Our focus on developing proprietary cannabinoid analogs over the past two years has started to pay dividends, evident in their utilization in these two new preclinical programs.”

“Concurrently, BayMedica continues to drive robust year-over-year revenue growth. The foreseeable future looks promising for the health and wellness segment as demand for minor cannabinoid ingredients continues to gain momentum.”

Key accomplishments in 2023

●

InMed completed a Phase 2 clinical trial of INM-755, studying its safety and efficacy in the treatment of symptoms related to Epidermolysis Bullosa (“EB”). The data showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream versus the control cream alone, warranting further development. For further detail on results, please see press release dated June 22, 2023. The study results were also selected as an oral presentation at the World Itch Congress in October 2023.

●

Launched INM-901 program following positive results from several proof-of-concept preclinical studies in a validated in vivo Alzheimer’s disease model.

●

Launched INM-089 program, expanding our ocular program into the treatment of AMD. In vivo models demonstrated promise in preserving retinal function and proactively protecting the retinal cells that are responsible for vision.

●

BayMedica experienced robust year-over-year revenues in each reported period.

Priorities for 2024

INM-901 in the treatment of Alzheimer’s Disease

The Company is highly encouraged by the initial preclinical data from in vitro and in vivo studies. Existing external research indicates that various cannabinoids have been shown to have a wide range of impact on Alzheimer’s pathology. Newly approved Alzheimer’s disease medications primarily address symptoms related to memory and cognitive function via the reduction of beta-amyloid plaques. Some approved treatments may slow the rate of cognitive decline, but no treatment has been shown to reverse disease effects. INM-901 appears to be active via multiple mechanisms of action; early research indicates INM-901 has the potential to be effective in reducing beta-amyloid plaques and has the potential to provide neuroprotective effects and enhanced neuronal function. Additionally, INM-901 treated groups demonstrated improved behavioral, cognitive and memory outcomes in several Alzheimer’s proof-of-concept studies using in vivo disease models.

The Company has initiated long-term (6-month) preclinical studies in behavioral models to further evaluate the potential impact of INM-901 in Alzheimer’s disease. Preparations are underway for the subsequent phase of advanced preclinical studies, encompassing drug distribution, metabolism and active pharmaceutical ingredient (“API”) and drug product formulation/ manufacturing.

INM-089 in the treatment of AMD

Based on the previous research conducted with InMed’s initial ocular drug candidate, INM-088 in the treatment of glaucoma, the Company leveraged its know-how to advance preclinical work with the use of a proprietary analog for the treatment of AMD. Our preclinical research has shown promising results in preserving retinal function, proactively protecting retinal cells, and enhancing the thickness of the outer nuclear layer of the retina where photoreceptors are situated.

The Company is currently engaged in API and drug product formulation work and expects to initiate Investigational New Drug (“IND”)-enabling studies in mid-2024, with the anticipation of filing an IND application with regulatory authorities in calendar 1H 2025.

INM-755 – In the treatment of EB

The comprehensive data and findings from the Phase 2 clinical trial will soon be available on the National Institutes of Health (“NIH”) clinicaltrials.gov website and the European Union Clinical Trials Register website. Additionally, an abstract will soon be published in Itch, the official journal of the International Forum for the Study of Itch.

The Company believes that INM-755 holds promise for further advancement in the treatment of chronic itch and other related ailments and the Company is currently seeking partnerships for continued development. Due to several factors, including the small size of the trial and the clinically important anti-itch activity of the underlying cream without study drug, results were not statistically significant, but we believe the results are clinically important based on additional analyses.

2

BayMedica – Ingredients supplier to the health and wellness industry

BayMedica continues to be a leading low-cost/high quality manufacturer of certain non-psychoactive rare cannabinoids and is an ingredients supplier to brands within the health and wellness industry. BayMedica demonstrated significant year-over-year revenue growth throughout 2023 and remains focused on making strategic decisions to capitalize on the revenue generation opportunities as the rare cannabinoid market continues to mature. BayMedica has embraced a predominantly distributor model to strategically expanding coverage across the US and thereby further amplifying BayMedica’s reach into different market segments. In 2024, we anticipate consumer brands will increasingly embrace rare cannabinoid ingredients, integrating them into new product formulations and formats.

About InMed: InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

Investor Contact:

Colin Clancy

Vice President, Investor Relations and Corporate Communications

T: +1 604 416 0999

E: cclancy@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: placing increased emphasis on proprietary small molecule drug development candidates; INM-901 shows promise via multiple mechanisms of action, including an increase in neuroprotection and an improvement in neuronal function via neuritogenesis and has potential to be effective in reducing beta-amyloid plaques; INM-089 appears to play a role in the preservation of retinal function, proactively protecting the retinal cells that are responsible for vision and enhancing the thickness of the outer nuclear layer of the retina; the foreseeable future looks promising for the health and wellness segment as demand for minor cannabinoids ingredients continues to gain momentum; the Company is highly encouraged by the initial preclinical data from in vitro and in vivo studies; preparations are underway for the subsequent phase of advanced preclinical studies, encompassing drug distribution, metabolism and API and drug product formulation and manufacturing; expecting to initiate IND-enabling GLP studies in mid-2024, with the anticipation of filing an IND in calendar 1H 2025; BayMedica making strategic decisions to capitalize on the revenue generation opportunities; anticipating brands increasingly embracing rare cannabinoid ingredients, integrating them into new product formulations and statements relating to the Company’s 2024 strategic priorities generally.

3

With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: continued economic, regulatory and market stability; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; and developing a pipeline of cannabinoid-based pharmaceutical drug candidates. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: regulatory filings may not be filed or approved on a timely basis, or at all. A more complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Security and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

4

GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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inm-20240116.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 inm-20240116_def.xml XBRL DEFINITION FILE EX-101.LAB 6 inm-20240116_lab.xml XBRL LABEL FILE Entity Addresses, Address Type [Axis] Former Address [Member] Entity Addresses [Table] Entity Addresses [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 inm-20240116_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Jan. 16, 2024
Entity Addresses [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jan. 16, 2024
Entity File Number	001-39685
Entity Registrant Name	INMED PHARMACEUTICALS INC.
Entity Central Index Key	0001728328
Entity Tax Identification Number	98-1428279
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	Suite 310 - 815 W. Hastings Street,
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6C 1B4
City Area Code	604
Local Phone Number	669-7207
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	INM
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Former Address [Member]
Entity Addresses [Line Items]
Security Exchange Name	NASDAQ

XML 9 ea191665-8k_inmedpharma_htm.xml IDEA: XBRL DOCUMENT 0001728328 2024-01-16 2024-01-16 0001728328 dei:FormerAddressMember 2024-01-16 2024-01-16 iso4217:USD shares iso4217:USD shares false 0001728328 A1 BC 8-K 2024-01-16 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street, Vancouver CA V6C 1B4 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 2 24 1 false 1 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea191665-8k_inmedpharma.htm inm-20240116.xsd inm-20240116_def.xml inm-20240116_lab.xml inm-20240116_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea191665-8k_inmedpharma.htm": { "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20240116", "dts": { "inline": { "local": [ "ea191665-8k_inmedpharma.htm" ] }, "schema": { "local": [ "inm-20240116.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "inm-20240116_def.xml" ] }, "labelLink": { "local": [ "inm-20240116_lab.xml" ] }, "presentationLink": { "local": [ "inm-20240116_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 2, "entityCount": 1, "segmentCount": 1, "elementCount": 64, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://inmedpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea191665-8k_inmedpharma.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea191665-8k_inmedpharma.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r15" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r15" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesTable", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r2" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r14" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r17" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r19" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r14" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "FormerAddressMember", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth_ref": [ "r13", "r16" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r21" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesLineItems", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r14", "r15" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r18" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r20" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r14" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "249", "Section": "308", "Subsection": "a" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Number": "249", "Section": "308" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r21": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001213900-24-003661-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-003661-xbrl.zip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end